Economic impact of stopping nilotinib in patients with CML in remission

  • PDF / 185,963 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 44 Downloads / 161 Views

DOWNLOAD

REPORT

73-5503/20/0861-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 5 Sep 2020 No. 861

1

Data Loading...

Recommend Documents
CML

165 99 4MB

Nilotinib

135 100 165KB

Nilotinib

133 70 166KB

Nilotinib

143 20 128KB

Nilotinib

142 109 166KB

Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practic

144 61 2MB

Residual Anxiety in Patients with Bipolar Disorder in Full or Partial Remission: Metacognitive Beliefs and Neurocognitiv

168 74 806KB

Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma

138 8 630KB

Nilotinib

134 7 166KB

CML

169 8 7MB

CML

183 118 65MB

Remission and Remission Prevention

158 14 35MB